Three-dimensional dosimetry for radioimmunotherapy treatment planning

George Sgouros, S. Chiu, K. S. Pentlow, L. J. Brewster, H. Kalaigian, B. Baldwin, F. Daghighian, M. C. Graham, S. M. Larson, R. Mohan

Research output: Contribution to journalArticle

Abstract

Absorbed-dose calculations for radioimmunotherapy are generally based on tracer imaging studies of the labeled antibody. Such calculations yield estimates of the average dose to normal and target tissues assuming idealized geometries for both the radioactivity source volume and the target volume. This work describes a methodology that integrates functional information obtained from SPECT or PET with anatomical information from CT or MRI. These imaging modalities are used to define the actual shape and position of the radioactivity source volume relative to the patient's anatomy. This information is then used to calculate the spatially varying absorbed dose, depicted in 'colorwash' superimposed on the anatomical imaging study. By accounting for individual uptake characteristics of a particular tumor and/or normal tissue volume and superimposing resulting absorbed-dose distribution over patient anatomy, this approach provides a patient-specific assessment of the target-to-surrounding normal tissue absorbed-dose ratio. Such information is particularly important in a treatment planning approach to radioimmunotherapy, wherein a therapeutic administration of antibody is preceded by a tracer imaging study to assess therapeutic benefit.

Original languageEnglish (US)
Pages (from-to)1595-1601
Number of pages7
JournalJournal of Nuclear Medicine
Volume34
Issue number9
StatePublished - 1993
Externally publishedYes

Fingerprint

Radioimmunotherapy
Radioactivity
Anatomy
Antibodies
Single-Photon Emission-Computed Tomography
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Sgouros, G., Chiu, S., Pentlow, K. S., Brewster, L. J., Kalaigian, H., Baldwin, B., ... Mohan, R. (1993). Three-dimensional dosimetry for radioimmunotherapy treatment planning. Journal of Nuclear Medicine, 34(9), 1595-1601.

Three-dimensional dosimetry for radioimmunotherapy treatment planning. / Sgouros, George; Chiu, S.; Pentlow, K. S.; Brewster, L. J.; Kalaigian, H.; Baldwin, B.; Daghighian, F.; Graham, M. C.; Larson, S. M.; Mohan, R.

In: Journal of Nuclear Medicine, Vol. 34, No. 9, 1993, p. 1595-1601.

Research output: Contribution to journalArticle

Sgouros, G, Chiu, S, Pentlow, KS, Brewster, LJ, Kalaigian, H, Baldwin, B, Daghighian, F, Graham, MC, Larson, SM & Mohan, R 1993, 'Three-dimensional dosimetry for radioimmunotherapy treatment planning', Journal of Nuclear Medicine, vol. 34, no. 9, pp. 1595-1601.
Sgouros G, Chiu S, Pentlow KS, Brewster LJ, Kalaigian H, Baldwin B et al. Three-dimensional dosimetry for radioimmunotherapy treatment planning. Journal of Nuclear Medicine. 1993;34(9):1595-1601.
Sgouros, George ; Chiu, S. ; Pentlow, K. S. ; Brewster, L. J. ; Kalaigian, H. ; Baldwin, B. ; Daghighian, F. ; Graham, M. C. ; Larson, S. M. ; Mohan, R. / Three-dimensional dosimetry for radioimmunotherapy treatment planning. In: Journal of Nuclear Medicine. 1993 ; Vol. 34, No. 9. pp. 1595-1601.
@article{52ac074c63964869ae94b44ff94f52b5,
title = "Three-dimensional dosimetry for radioimmunotherapy treatment planning",
abstract = "Absorbed-dose calculations for radioimmunotherapy are generally based on tracer imaging studies of the labeled antibody. Such calculations yield estimates of the average dose to normal and target tissues assuming idealized geometries for both the radioactivity source volume and the target volume. This work describes a methodology that integrates functional information obtained from SPECT or PET with anatomical information from CT or MRI. These imaging modalities are used to define the actual shape and position of the radioactivity source volume relative to the patient's anatomy. This information is then used to calculate the spatially varying absorbed dose, depicted in 'colorwash' superimposed on the anatomical imaging study. By accounting for individual uptake characteristics of a particular tumor and/or normal tissue volume and superimposing resulting absorbed-dose distribution over patient anatomy, this approach provides a patient-specific assessment of the target-to-surrounding normal tissue absorbed-dose ratio. Such information is particularly important in a treatment planning approach to radioimmunotherapy, wherein a therapeutic administration of antibody is preceded by a tracer imaging study to assess therapeutic benefit.",
author = "George Sgouros and S. Chiu and Pentlow, {K. S.} and Brewster, {L. J.} and H. Kalaigian and B. Baldwin and F. Daghighian and Graham, {M. C.} and Larson, {S. M.} and R. Mohan",
year = "1993",
language = "English (US)",
volume = "34",
pages = "1595--1601",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "9",

}

TY - JOUR

T1 - Three-dimensional dosimetry for radioimmunotherapy treatment planning

AU - Sgouros, George

AU - Chiu, S.

AU - Pentlow, K. S.

AU - Brewster, L. J.

AU - Kalaigian, H.

AU - Baldwin, B.

AU - Daghighian, F.

AU - Graham, M. C.

AU - Larson, S. M.

AU - Mohan, R.

PY - 1993

Y1 - 1993

N2 - Absorbed-dose calculations for radioimmunotherapy are generally based on tracer imaging studies of the labeled antibody. Such calculations yield estimates of the average dose to normal and target tissues assuming idealized geometries for both the radioactivity source volume and the target volume. This work describes a methodology that integrates functional information obtained from SPECT or PET with anatomical information from CT or MRI. These imaging modalities are used to define the actual shape and position of the radioactivity source volume relative to the patient's anatomy. This information is then used to calculate the spatially varying absorbed dose, depicted in 'colorwash' superimposed on the anatomical imaging study. By accounting for individual uptake characteristics of a particular tumor and/or normal tissue volume and superimposing resulting absorbed-dose distribution over patient anatomy, this approach provides a patient-specific assessment of the target-to-surrounding normal tissue absorbed-dose ratio. Such information is particularly important in a treatment planning approach to radioimmunotherapy, wherein a therapeutic administration of antibody is preceded by a tracer imaging study to assess therapeutic benefit.

AB - Absorbed-dose calculations for radioimmunotherapy are generally based on tracer imaging studies of the labeled antibody. Such calculations yield estimates of the average dose to normal and target tissues assuming idealized geometries for both the radioactivity source volume and the target volume. This work describes a methodology that integrates functional information obtained from SPECT or PET with anatomical information from CT or MRI. These imaging modalities are used to define the actual shape and position of the radioactivity source volume relative to the patient's anatomy. This information is then used to calculate the spatially varying absorbed dose, depicted in 'colorwash' superimposed on the anatomical imaging study. By accounting for individual uptake characteristics of a particular tumor and/or normal tissue volume and superimposing resulting absorbed-dose distribution over patient anatomy, this approach provides a patient-specific assessment of the target-to-surrounding normal tissue absorbed-dose ratio. Such information is particularly important in a treatment planning approach to radioimmunotherapy, wherein a therapeutic administration of antibody is preceded by a tracer imaging study to assess therapeutic benefit.

UR - http://www.scopus.com/inward/record.url?scp=0027225966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027225966&partnerID=8YFLogxK

M3 - Article

C2 - 8394886

AN - SCOPUS:0027225966

VL - 34

SP - 1595

EP - 1601

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 9

ER -